Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 3/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 6/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91862 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CYP2A6KIF11PDE3BPDE3A | |
| SCHEMBL19608729 | 0.92 | ALDH1A1 (0.50) | ALDH1A1CYP2A6KIF11PDE3BPDE3A | |
| SCHEMBL397141 | 0.91 | KIF11 (0.61) | KIF11PDE3BPDE3ACYP11B2CYP11B1 | |
| SCHEMBL91880 | 0.90 | ALDH1A1 (0.52) | ALDH1A1CYP2A6KIF11PDE3BPDE3A | |
| SCHEMBL28428605 | 0.90 | ALDH1A1 (0.52) | ALDH1A1CYP2A6KIF11PDE3BPDE3A | |
| SCHEMBL16945886 | 0.86 | AR (0.48) | ALDH1A1CYP2A6KIF11PDE3BPDE3A | |
| SCHEMBL170435 | 0.86 | PDE3B (0.49) | PDE3BPDE3AARPDK2 | |
| SCHEMBL16945958 | 0.85 | KIF11 (0.47) | ALDH1A1CYP2A6KIF11PDE3BPDE3A | |
| SCHEMBL19308493 | 0.85 | KIF11 (0.54) | KIF11PDE3BPDE3ACYP11B2CYP11B1 | |
| SCHEMBL15834358 | 0.85 | KIF11 (0.54) | KIF11PDE3BPDE3AKDM1ACYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667840-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11208594-B2 | Liquid-crystalline medium and high-frequency components comprising same | MERCK PATENT GMBH (DE) | 2021-12-28 | — | — | US | disclosed |
| US-10975308-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2021-04-13 | — | — | US | disclosed |
| EP-3529331-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-10-07 | — | — | EP | disclosed |
| US-10676670-B2 | Liquid-crystalline medium and high-frequency components comprising same | MERCK PATENT GMBH (DE) | 2020-06-09 | — | — | US | disclosed |
| US-10662377-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2020-05-26 | — | — | US | disclosed |
| EP-3504293-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-05-13 | — | — | EP | disclosed |
| EP-3433337-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-10550326-B2 | Liquid-crystalline medium and high-frequency components comprising same | MERCK PATENT GMBH (DE) | 2020-02-04 | — | — | US | disclosed |
| EP-3140369-B1 | LIQUID-CRYSTALLINE MEDIUM AND HIGH-FREQUENCY COMPONENTS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-20090267025-A1 | LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090247620-A1 | Benzochromene Derivatives for Use in Liquid Crystal Media and as Therapeutic Active Substances | MERCK PATENT GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-7531106-B2 | Mesogenic compounds, medium for electro-optical displays and electro-optical display | MERCK PATENT GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20090023802-A1 | Benzochromene Derivatives | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| US-7440160-B2 | Electro-optical light modulating element, electro-optical display and modulating medium | MERCK PATENT GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20080177095-A1 | FUROCHROMAN DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080167482-A1 | mesogenic group is linked to the C-atom No. 5 of the 1,3-dioxane-5-yl group; media showing a blue phase and their use in electro-optical light modulation elements | MERCK PATENT GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7361288-B2 | Components for high-frequency technology | MERCK PATENT GESELLSCHAFT MIT BESSCHRANKTER HAFTUNG (DE) | 2008-04-22 | — | — | US | disclosed |
| US-7326447-B2 | Benzochromene derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177095-A1 | FUROCHROMAN DERIVATIVES | CFD, LMAN1, UROD | ALDH1A1 1075/4885CYP2A6 2847/4885KIF11 2305/4885 |
| US-20090247620-A1 | Benzochromene Derivatives for Use in Liquid Crystal Media and as Therapeutic Active Substances | LPO, SBDS, OCIAD1 | ALDH1A1 1625/4885CYP2A6 1448/4885KIF11 3176/4885 |
| US-20090023802-A1 | Benzochromene Derivatives | SBDS, CRY1, DDT | ALDH1A1 676/4885CYP2A6 269/4885KIF11 4044/4885 |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | CRY1, CRY2, IK | ALDH1A1 2978/4885CYP2A6 2777/4885KIF11 330/4885 |
| US-11667840-B2 | Liquid-crystalline medium | FES, BLM, CXCL12 | ALDH1A1 3893/4885CYP2A6 3564/4885KIF11 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.